Skip to main content

Table 1 Comparison of the sensitivity, specificity and positive rate of QFT-PLUS and QFT-GIT

From: Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis

 

Studies (n)

Participants (n)

QFT-PLUS positive

I2 (%)

QFT-GIT positive

I2 (%)

RD-test

I2 (%)

Active TB

12

1004

0.886 (0.812–0.944)

87

0.879 (0.802–0.939)

87

0.01 (− 0.02–0.03)

0

Populations with very low risk of TB exposure

5

482

0.987 (0.961–0.999)

65

0.996 (0.984–1.000)

28

0.00 (− 0.02–0.01)

0

High-risk populations

18

4617

0.235 (0.154–0.328)

97

0.228 (0.144–0.323)

97

0.02 (0.01–0.03)

0

 Recent contacts

7

1391

0.311 (0.185–0.453)

97

0.286 (0.167–0.423)

97

0.02 (0.00–0.05)

0

 Immunocompromised patients

4

850

0.317 (0.107–0.578)

95

0.304 (0.090–0.578)

96

0.01 (− 0.02–0.05)

0

 With possibility of contact

6

2147

0.108 (0.039–0.205)

98

0.119 (0.027–0.264)

98

0.02 (0.00–0.03)

37

 With possibility of immunosuppression

1

229

NA

NA

NA

NA

0.03 (− 0.05–0.12)

0

  1. QFT-Plus QuantiFERON-TB Gold Plus, QFT-GIT QuantiFERON-TB Gold In-Tube